Another interesting aspect from the HERCULES tolebrutinib phase 3 clinical trial results published in the NEJM

“Most of the participants (74.0%) had previously received one or more disease-modifying therapies…” (page 4).

This suggests that the DMTs did not do much, if anything, to prevent people from transitioning to nrSPMS.

Published by

kaylin bower

Multiple Sclerosis Research Repository